

Freedom of Information Request	FOI 22-402	15 <sup>th</sup> September 2022
--------------------------------	------------	---------------------------------

**Q1. How many patients has your trust treated (for any disease) in the last 6 months (or the latest 6 months data you have available) with the treatments listed below:**

- **Revolade (eltrombopag)**
- **Nplate (romiplostim)**
- **Doptelet (avatrombopag)**
- **Tavlesse (fostamatinib)**

Please find below the quantities dispensed from the Health Board pharmacies for the period March 2022 – August 2022 for any disease.

Please note the Health Board is only able to supply information by quantity and not by the number of patients treated:

Description	Quantity
AVATROMBOPAG 20 mg Tablets 10 Tablet Pack	9
ELTROMBOPAG 25 mg Tablets 28 Tablet Pack	10
ELTROMBOPAG 50 mg Tablets 28 Tablet Pack	16
ROMIPLOSTIM 125 micrograms Subcutaneous Injection 1 Vial Pack	117
ROMIPLOSTIM 250 micrograms Subcutaneous Injection 1 Vial Pack	487

**Q2. In the last 6 months (or the latest 6 months data you have available), how many patients has your trust treated for immune thrombocytopenia (ITP)?**

Approximately 90 patients.

**Q3. Of the patients treated for immune thrombocytopenia (ITP) in the last 6 months (or the latest 6 months data you have available), how many were treated with:**

- **Rituximab** = 0
- **mycophenolate mofetil** = 0
- **surgery (splenectomy)** = <5

Please note where less than five (5) patients have been identified, Section 40 of the Freedom of Information Act 2000 has been applied as the Health Board cannot provide the exact numbers due to the low numbers of individuals involved (5 or less). The Health Board believes there is a potential risk of individuals being able to be identified, when considered with other information already available within the public domain, if this was disclosed. Therefore, the data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute unfair and unlawful processing in regard to Articles 5, 6, and

9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

**Q4. Does your trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?**

The Health Board are running the UK ITP registry. The Health Board has 107 recruits in total across all sites, with 53 in active follow up.